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Intracellular Defenses Against HIV, Viral Evasion 
and Novel Therapeutic Approaches
Robert A Lever, Andrew M L Lever*
Human immunodeficiency virus (HIV), the causative agent of AIDS, is a retrovirus. It is estimated that,
while in the cell, it interacts with almost 10% of cellular proteins. Several of these have evolved to protect
the cell from infection with retroviruses and are known as “restriction factors”. Restriction factors tell us
much about how the virus functions and open up new paradigms for exploring novel antiviral therapeutics.
This article gives an update on the three best studied restriction factors, their putative mechanisms of action
and how the virus has overcome their effects, together with an indication of novel therapeutic approaches
based on this knowledge.
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Although human immunodeficiency virus (HIV)
has had a devastating effect on the human race
since it was first identified in the last few decades of
the last century, it is not the first pathogen to do
this, and it follows a recognizable pattern in that
infections that cross from other species (zoonoses)
commonly cause much more severe disease in
their new host. In addition, HIV is not the first
pathogenic retrovirus to infect humans. One other,
HTLV-1, is almost as widespread1 but, because of
its very long association with the human species,
both have adapted to each other and now it is of
low pathogenicity, except in a small percentage
of individuals in whom it causes disease.
The adaptive immune system is often thought
of as our major defense against such invaders,
but in fact, only vertebrates have this type of im-
munity, and invertebrates seem to resist infec-
tions well in general. The innate immune system,
a much underrated defense network, has a large
and diverse armamentarium against those infec-
tions to which we have been exposed for many
years. As relics of our past encounters with patho-
gens, and presumably for other contemporary
purposes, a number of intracellular proteins exist
that are there to block virus infection. These are
known as “restriction factors” and they comprise
a growing family of gradually better understood
cellular guardians. Restriction factors are often
highly conserved, intimating at their essential
nature, and they offer us a new insight into ways
in which we might target invading pathogens by
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manipulating processes that have evolved natu-
rally over many millions of years. This review fo-
cuses on three protein restriction factors that are
important in the case of HIV infection. In all cases
the defensive factor has been countered by strate-
gies of HIV. There may be a symbiosis in which
the virus uses the effect of the factor for its own
purposes, or HIV has evolved an escape mecha-
nism by generating its own interfering protein
that nullifies the effect of the restriction factor.
Another strategy of HIV is to hijack a second cel-
lular protein for its own protection. The sites of
action of the restriction factors and the counter
measures of the virus are shown in the Figure.
TRIM5a
Simian immunodeficiency viruses such as SIVsm,
SIVagm and SIVmac (the last of which has the
highest sequence homology with HIV-1) are all
able to infect immunological cells from old world
monkeys (OWM) yet these latter resist in vitro in-
fection with HIV-1.2–6 Even getting the virus in
by a “Trojan horse” approach of putting it in a
new coat (“pseudotyping” it with VSV-G), which
guarantees entry, does not overcome this so called
“monkey block” telling us that the effect is oc-
curring at a stage after viral entry. The restriction
can be overcome experimentally by introducing
an excess of virus cores into the cell, suggesting
that an inhibitory factor is present that can be
“saturated out”. This factor was initially named
Lv1 (lentiviral susceptibility factor 1).7–10 In seek-
ing to identify this factor, a mouse gene vector pop-
ulation containing a cDNA library of the genome
of Rhesus macaques was introduced into (human)
HeLa cells in culture, which were then challenged
with VSV-G pseudotyped HIV and SIV vectors,
and any cells which were resistant to infection by
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Figure. Sites of restriction factor action.
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HIV were isolated and grown out.11 The resulting
resistant clones were found to express a protein
called simian TRIM5α. Knockdown of this protein
by short interfering RNA abolished the blocking
effect. The effect of TRIM5α was dependent on
the viral capsid. Corroborating evidence soon
followed from unexpected findings when Owl
Monkey cells were challenged with HIV.12,13 The
Owl Monkey is a New World monkey, and as such
would not be expected to constitutively restrict
HIV-1, yet it showed a block of the same charac-
ter as OWM cells. Analysis of the Owl Monkey
TRIM5α sequence showed that it had fused with
another cellular gene, cyclophilin A (CypA), which
had previously been identified as a positive (infec-
tion enhancing) co-factor in early HIV-1 infection
through its interaction with the p24 CA (capsid)
protein of the virus, an effect that can be inhib-
ited by the immunosuppressant drug and CypA
inhibitor, cyclosporine A.12,14 This fusion protein
was named TRIMCyp, and it was hypothesized
that the CypA sequence targeted the TRIM to 
the entering viral core, an idea supported by the
elimination of restriction activity in cells treated
with cyclosporine A.
TRIM is an abbreviation for Tripartite Motif,
which refers to a group of three recognizably sim-
ilar amino acid sequences (domains) found in 
a large family of proteins. These comprise an N-
terminal RING (Really Interesting New Gene)
domain, a B-box and a coiled coil. The protein
family is large, with at least 68 members perform-
ing multiple functions within cells. Apart from
antiviral activity, they have also been implicated
in development and oncogenesis.15–18 Present in
cytoplasmic bodies, TRIM5α is universally and
constitutively expressed while being under the
control of the interferon sensitive IRF3 promoter,
and is therefore upregulated in response to type I
interferon.19–21 The RING domain contains a
zinc binding motif generally found in proteins that
have E3 ubiquitin ligase activity.22 This suggested
that TRIM5 may undergo auto-ubiquitination and
might also ubiquitinate other proteins.23,24 The
B-box is needed for the retroviral restriction ac-
tivity, and point mutations of essential residues
have been shown to eliminate the HIV-1 block.25–27
Despite this, its function is obscure and it may be
important for formation of higher order struc-
tures, intracellular localization and/or protein
turnover.28 Oligomerization represents the major
function of the coiled-coil domain, where large
numbers of α helices mediate protein-protein in-
teractions thought to be important in the produc-
tion of multimers. The major functional form of
TRIM5α was believed to be a trimer,29,30 but an
elegant report in 2008 demonstrated that cross
linkage of TRIM5α dimers bestowed anomalously
slow electrophoretic mobility on the complex,
making them appear trimeric.31 The coiled coil
may also contribute to species specificity.32 The
B30.2/SPRY C-terminal domain is responsible for
viral capsid recognition and binding. This region
contains non-structured interconnecting “vari-
able” loops (v1–v4), which are critical for this
function. Alterations in the sequence and structure
of this domain are the most important factor in
determination of species specificity of the TRIM5α
protein.33–38 The critical sequence contains PRY
and SPRY domains.27,34,39 The viral specificity 
of different TRIM5α proteins is concentrated in
these regions.33 One particular single amino acid
substitution is of particular interest — a change
from arginine to any non-positively charged amino
acid at position 332 in the human TRIM5α ele-
vates the potency of restriction against HIV-1 to
that of the OWM TRIM5 molecules.
The exact mechanism by which TRIM5α bind-
ing effects retroviral restriction has yet to be 
elucidated. There are arguments for pathways
both dependent (addition of ubiquitin and sub-
sequent degradation)40 and independent of the
proteasome.31,41 The RING domain possesses E3
ubiquitin ligase activity, and a recent paper set
out to establish the effect of this activity in HIV
restriction.42 Previously, Rhesus macaque (Rh)
TRIM5α activity had been shown to be reduced
by addition of a proteasomal inhibitor.43,44 The
authors pursued this further and ascertained that
the proteasomal dependence of restriction of dis-
tinct retroviruses is virus specific. For example
proteasomal inhibition attenuated SIVmac block,
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but had no effect on HIV-1 restriction by an African
Green Monkey TRIM5α. It seems likely that, rather
than polyubiquitinating the capsid protein itself,
TRIM5α binds to the CA subunit and targets it-
self for degradation, a proposal supported by the
potent ability of TRIM5α to auto-ubiquitinate.24
The proteasomal independent pathway45 may
involve direct disassembly of viral cores, as has
previously been demonstrated in cytoplasmic as-
says.46 There is wide sequence divergence between
TRIM5α in different primate species. However,
there is remarkable sequence conservation in the
human B30.2 domain within the human popu-
lation, and specifically a complete absence of
polymorphisms within the N-terminal region com-
prising the variable loops (V1–3).47 This lack of
diversity is unusual. It is speculated that the human
sequence reflects evidence of a previous retrovi-
ral pandemic leading to a major survival benefit
of the current version. Ironically the uniformity of
the human TRIM5α gene could have contributed
to the virtual universal susceptibility of humans
to HIV and the consequent scale of the current
HIV pandemic.48 Several SNPs have been identi-
fied elsewhere in the gene, one in particular, the
H43Y mutation, which shows alteration in activity
in vitro attenuating TRIM5α activity. However, the
clinical phenotype is inconsistent with protective,49
neutral,50 and negative effects described.51
Gene therapy experiments exploring potential
applications for TRIM5α based HIV-1 treatment
have used lentiviral vectors to express RhTRIM5α
in a hematopoietic stem cell line that subsequently
differentiated into HIV-1 resistant macrophages.52
Combination vectors such as those containing a
TAR decoy, CCR5 shRNA and a chimeric TRIM5α
have also been shown to be effective in HIV-1 
restriction in primary macrophages in vitro and
probably represent a fruitful avenue for further
gene therapy work.53 An alternative has been to
fuse cyclophilin A to the wild type human TRIM5α
allele,54 exploiting the fact that the basic defect
in human TRIM5α mediated HIV-1 restriction is
failure of B30.2 recognition. The investigators
have effectively mimicked in vitro the process that
Aotus sp and certain Macaca Old World Monkeys
achieved by retrotransposition in vivo. Of note,
one particular construct of this fusion protein has
been shown to be more effective than the wild
type Rhesus TRIM5α itself, and highly resistant
to the evolution of viral resistance, both excellent
signs for a potential gene therapy agent. Cyclophilin
based strategies have also been explored in cats
in attempts to restrict Feline Immunodeficiency
Virus (FIV). This much underexploited animal
model of HIV infection is well suited to such
therapeutic trials.55
The APOBEC3 family and the vif gene
HIV-1 is a “complex” retrovirus, and as such codes
for a variety of accessory and regulatory genes, 
in addition to the genes gag, pol and env that en-
code the structural proteins.56 One of the acces-
sory gene products, Vif, is a 23kDa highly basic
protein that has long been known to be essential
for in vivo viral replication, but is inconsistently
required for infection of certain CD4+ T cell
lines.57–61 Exploitation of these in vitro differences
between “permissive” cell lines [susceptible to
infection with a Vif deleted (vif) virus] and
“non-permissive” cell lines (non-susceptible) led
to the gradual elucidation of the in vivo function
of the Vif protein, and ultimately the discovery
of a new class of restriction factors.62 The first
step was identifying whether there was an essen-
tial positive factor in permissive cells emulated by
Vif in non-permissive cells, or whether the actions
of Vif were to overcome the inhibitory effects of a
gene which was only expressed in non-permissive
cells. Hybrid permissive/non-permissive cell lines
were created and infection with vif HIV-1 yielded
defective virions, suggesting that Vif was acting
to sabotage a cellular factor present only in non-
permissive cells. Identification of this restriction
factor followed 4 years later in an elegant series
of experiments where the investigators first used
subtractive hybridization to screen the transcrip-
tome of non-permissive CEM cells versus a per-
missive version of the same cell line from which
a candidate protein was identified. They then de-
monstrated reconstitution of the non-permissive
phenotype by artificially expressing the protein in
R.A. Lever, A.M.L. Lever
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permissive CEM-SS cells. This protein, APOBEC3G,
is now recognized as a member of a family of 
cytidine deaminases, which operate to defend
against exogenous retroviruses, endogenous re-
troelements and a variety of other viruses includ-
ing the hepatitis B virus.63,64 APOBEC3 proteins
(so called due to their homology to the mRNA
editing enzyme APOBEC1) are unique to mam-
mals and are involved in DNA editing and mu-
tation.65 They have arisen via gene duplication
on chromosome 22 and comprise seven genes 
in humans (APOBEC3A, 3B, 3C, etc through 
to APOBEC3H).65,66 APOBEC3G (hA3G) and
APOBEC3F (hA3F) are expressed in primary T
cell lines, monocytes and macrophages rendering
these cells resistant to vif deficient virus ex vivo.67
Permissive cells produce Vif deficient virus that is
infectious to non-permissive cells in single cycle
assays, but Vif deficient virus produced from non-
permissive cells is unable to replicate even in
permissive cells.68,69 This observation, in combi-
nation with the identification of hA3G in mature
virions from permissive cell lines, intimated that
the major site of hA3G action was prior to inte-
gration of the viral (proviral) DNA into the host
cell chromosomes. It has since been shown that
in vif mutants, hA3G bind both the viral nucle-
ocapsid (NC) protein and viral genomic RNA and
acts during the process of viral reverse transcription.
During negative strand synthesis, hA3G is released
by the action of RNase H at which point the single
negative strand of viral cDNA is exposed.70 hA3G
then acts to deaminate cytidine to uridine on this
strand.71–77 Destruction of the heavily mutated
DNA by cellular factors may then occur resulting in
elimination of the proviral genome mid-reverse
transcription.78–80 If, however, the DNA is not
destroyed, the deaminated cytosines on the DNA
act as templates for adenine incorporation into
the opposite (positive) strand of the immature
proviral sequence. The subsequent GA muta-
tions result in missense or nonsense manipulation
of the code, generally producing non-functional
viral proteins post-integration, inhibiting further
viral replication. Deamination of cytidines prob-
ably represents the most important activity of hA3
physiologically; however, several studies have re-
ported a deaminase independent effect on viral
and retroelement restriction,81–86 and hA3 has
been suggested to have a deaminase-independent
effect on HIV-1 replication.87–92 Criticisms at some
of these studies have centered around the fact
that they have relied on transient overexpression
of hA3 genes (specifically hA3G and hA3F) at
non physiological levels; however, since antiviral
genes such as hA3G are likely to be upregulated
in response to interferon in vivo,93 it may not be a
totally artificial scenario. In vivo, however, the virus
only ever encounters deaminase competent A3G
and A3F, and that activity may be so dominant that
the alternative effects are minor or artifactual.
In general only hA3 proteins with two zinc
binding domains can restrict HIV-1 to any signif-
icant degree and of these, only two, APOBEC3G
and APOBEC3F, have noteworthy action (although
several others have modest effects on HIV-1).94,95
The presence of two zinc binding domains confers
on these proteins the ability to homo-oligomerize
in a context dependent manner.96–98 Low molec-
ular weight multimers are surmised to assemble
in response to the presence of RNA and appear
to be active in restriction, whereas higher molec-
ular weight multimers complexed with RNA are
not functional.99 Vif operates to antagonize hA3G
function in several ways, but primarily acts in a
proteasome dependent fashion via the ubiqui-
tination of hA3G.100–104 Vif links hA3G to the
ELONGINB/C-CULLIN5-RBX1 E3 ubiquitin lig-
ase resulting in polyubiquitination and 26S pro-
teasomal degradation.105 In addition to this, Vif
reduces translation of the hA3G mRNA in vitro
by two independent mechanisms, the more im-
portant of which relies on Vif binding to the 5’
UTR of hA3G mRNA.106 The co-evolution of Vif
and A3G/A3F may represent a balance, as the
mutagenic effect of APOBEC3 seems to have, in
moderation, an advantageous effect in accelerating
viral genomic mutation, and therefore immune
escape and development of drug resistance.107–112
Evidence for this partnership includes the per-
sistence of new GA mutations in appropriate
contexts present in HIV-1 clinical isolates and the
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preponderance of these changes in drug resist-
ance genes. The most obvious therapeutic target
in this process is the disruption of Vif mediated
antagonism of hA3G and hA3F function. Clearly
such manipulation could be achieved pharma-
ceutically by interruption of the binding of the
two proteins by blocking the interacting surface
on either the human or the viral protein. There is
a small possibility that, by enhancing APOBEC3
function, a correspondingly higher mutation rate
would predispose to an even more rapid produc-
tion of highly drug and immune resistant viruses
than is currently achieved by wild type virus.
However, given the close relationship between
Vif and APOBEC3 evolution, it seems likely that
the current APOBEC induced mutation rate is
optimal for HIV-1 survival. Another therapeutic
approach would be the development of inhibitors
targeted at binding the cellular hA3G. This ap-
proach has a number of advantages. (1) Altering
hA3 action places the selection pressure on the
stable cellular protein rather than the highly mu-
table Vif. (2) In contrast to the regions of Vif that
bind hA3, the sequence binding Vif on hA3G 
is continuous, facilitating the design of specific
shielding molecules.113–118 Potential dangers of
this strategy are related to the concept that hA3
proteins may also mutate cellular DNA, and this
effect may be exaggerated to a harmful extent by
enhancing their action.119 Finally the homozygous
absence of hA3B in certain human populations
suggests that there may be a selective disadvan-
tage to increased hA3 activity potentially through
damaging hypermutation of DNA.120 It is of note,
however, that while there is no clinical phenotype
associated with hA3B-/-, polymorphism studies
have associated this genotype with increased risk
of infection, faster progression to AIDS and an
increase in baseline viraemia.121
Several small molecule inhibitors have been
identified whose aim is to potentiate hA3G ac-
tion via Vif inhibition. The first, RN-18, was shown
to have efficacy through a screen of possible Vif
antagonists.122 It acts at the point of Vif induced
recruitment of the E3 ubiquitin ligase complex
prior to proteasomal degradation of hA3G by
misdirecting polyubiquitination from hA3G onto
the Vif molecule itself. This results in Vif destruc-
tion by the 26S proteasome, lower constitutive
Vif effects and liberates the activity of hA3G 
allowing its incorporation into budding virions.
More recently two further potential therapeutic
inhibitors have been isolated from the collection at
the Chinese Academy of Medical Sciences. IMB26
and IMB35 are analogous compounds found to
disrupt Vif mediated degradation of hA3G. A
negative effect on HIV-1 infectivity was shown with
these compounds in vitro, which varied widely
between T-cell lines and was positively related to
APOBEC3G mRNA expression in the compound
treated cells.123 The authors were able to illus-
trate a direct interaction between IMB26/35 and
hA3G and showed that, in contrast to RN-18, they
acted to block Vif binding, rather than having 
a negative effect on Vif levels. Of note they also
observed no increase in hA3G activity in the
presence of the compound and an LD50 in vivo
well outside any therapeutic range.123 Clinically
a number of studies have associated higher hA3G
expression with elevated CD4+ counts and re-
duced viral set point,124 however some reports
cast doubt on these findings.125–128 Exposed un-
infected individuals appear to express higher lev-
els of APOBEC3G compared with those that are
infected.129
BST-2/tetherin
The viral accessory protein Vpu was first shown
to be important in viral release in 1990, when its
deletion resulted in viral accumulation in endo-
somes and on the cell surface.130 Such viral re-
tention was later shown to be cell type specific,
and resembled the reaction seen in response to
type I interferon.131–134 The cell specificity of Vpu
dependence was initially examined using fusions
between cells of two cell lines exhibiting differ-
ential Vpu requirements. The results suggested the
presence of a dominant cellular restriction factor
antagonized by Vpu, a conclusion supported by
the observation that exogenous Vpu could result
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in release of an unrelated virus from the effects of
this as yet unidentified cellular mechanism.134,135
The retention imposed by this cellular factor was
later shown to be relieved by exposure of the
cells to subtilisin, a proteolytic enzyme, suggest-
ing a cellular membrane bound protein was ex-
erting the observed effect. The key discovery as to
the identity of this protein was made almost si-
multaneously by two separate groups in 2008.
Neil et al used a microarray comparison to see
differences in the expression profile of Vpu de-
pendent (HeLa) and Vpu independent (COS-7)
cell lines that might account for their differential
restriction. They identified the previously described
BST-2, which they renamed tetherin in recogni-
tion of its action.136 Van Damme et al made a
similar discovery by following up some of their
previous work on the K5 protein of the Kaposi’s
Sarcoma Herpes Virus (KSHV), which they had pre-
viously described as downregulating BST-2.137,138
Tetherin is a 30–36 kDa type II membrane glyco-
protein with an unusual structure.139 Its N-terminal
is an intracytoplasmic tail linked to a membrane-
spanning alpha helical domain leading to a
coiled-coil ectodomain and ending in a glyco-
sylphosphatidylinositol (GPI) anchor at the C-
terminus of the protein. The intracellular domain
of tetherin contains a variety of important mo-
tifs; specifically a YxY domain mediating clathrin-
linked endocytosis,140 a KxxK motif targeted by
the KSHV K5 protein,141 and in non-human pri-
mates, a DDIWK sequence targeted by Nef both
of the latter leading to degradation.142 The coiled-
coil consists of two alpha helices containing three
cysteines mediating disulphide bonding and two
asparagines representing putative glycosylation
sites in the ectodomain, although the impor-
tance of both of these conserved residues is dis-
puted.143,144 Interestingly this coiled-coil structure
is only metastable, being held together by disul-
phide bonds with conserved destabilizing amino
acids resulting in the potential to form a rod like
structure.145 At the C-terminal, the GPI tail an-
chors the distal end of the protein in the mem-
brane, allowing its localization to cholesterol rich
lipid rafts,139,146 a preferential site of HIV-1 (and
Ebola virus) budding.147 Apart from its strange
arrangement, it is also atypical in that it is endocy-
tosed in a clathrin dependent manner,140 a feature
highly unusual in a GPI linked protein.
Tetherin is under the transcriptional control
of type I interferons which are released as part of
the inflammatory response to HIV-1 via the stim-
ulation of Toll Like Receptors (TLR) 7 and 9 in
plasmacytoid dendritic cells.148–151 The tetherin
promoter contains an interferon response ele-
ment (IRE) and three STAT3 response sites, al-
lowing it to be induced by interleukin 6 and other
stimulators of the JAK-STAT cascade.152 The mech-
anism of action of tetherin is not well described,
and contains several areas of contention. In the
absence of Vpu activity, tetherin causes the reten-
tion of virions on the cell surface and in endoso-
mal vesicles. This capture effect can be released
either by physical shearing or by subtilisin treat-
ment, resulting in the production of mature, func-
tional virions.143,153 The direct tethering of virions
by tetherin has been supported by tetherin co-
localizing with Gag.136,154 Since several virus types
are restricted by tetherin, any model involving
specific interaction with a viral protein is highly
unlikely, and a plausible idea is one in which one
membrane anchor of tetherin is positioned in
the cell membrane and the other in the viral en-
velope forming a physical bridge between them
and preventing release.
Tetherin has been shown to dimerise,144 but
how this occurs and its functional significance
are both unknown. Vpu is a 16 kDa Type I trans-
membrane protein whose functions include not
only antagonism of tetherin, but also downregu-
lation of CD4. It is unusual in that it is not pres-
ent in most primate lentiviruses (including HIV-2),
despite the highly conserved function of tetherin.
Other accessory viral gene products such as Nef
and Env substitute its function in many simian
lentiviruses.142,155,156 The tetherin transmembrane
(TM) domain confers sensitivity and species speci-
ficity to Vpu as shown by experimental domain
swapping to produce Rhesus-human fusion pro-
teins.157,158 It is also suggested by the high rate 
of non-synonymous mutations in this region. 
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In addition, a Vpu TM-mutant, still able to down-
regulate CD4, failed to negate the effects of teth-
erin.159 Downmodulation of cell surface tetherin
expression could be related to either destruction
or reduction in total cell tetherin, or could be an
outcome of retention of tetherin in intracellular
compartments. Immunoblot analyses suggest the
overall effect includes a direct downregulation of
total cell tetherin, an observation supported by
the effect of various lysosomal and ubiquitin in-
hibitors on Vpu action.160–164 Vpu deficient viruses
can still replicate, although they show more of a
propensity to form syncytia with little free virion
formation. This observation in itself implicates
Vpu as a viral fitness factor possibly important in
the transmission of HIV-1 via bodily fluids.155 As
yet, apart from involving the interferon system,
there are no specific novel antiviral approaches
to HIV involving the tetherin system.
Conclusion
This review has illustrated a small area of the in-
timate interaction that occurs between a viral
pathogen such as HIV and the cells of its host. It
emphasizes that we have much to learn about anti-
viral approaches from the innate immune system.
Since to date there has been virtually complete
failure to achieve protection from HIV infection
by conventional approaches using the adaptive
immune system, which has been so successfully
exploited for other viral pathogens, it merits fur-
ther investigation as to how we can use these an-
cient viral defense mechanisms to enhance our
attempts at therapy and prevention of HIV/AIDS.
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